Form 4: MYGN CFO Granted 60,000 Restricted Stock Units

Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, was granted 60,000 restricted stock units, increasing his beneficial ownership to 95,210 shares.

Summary

• Chief Financial Officer Benjamin Richard Wheeler acquired 60,000 shares of common stock.
• The acquisition was a grant of time-based restricted stock units (RSUs) under the Company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• These RSUs were granted at a price of $0 per unit and represent a contingent right to receive one share of the Company's common stock per unit.
• The RSUs are scheduled to vest in three equal annual installments, beginning on the first anniversary of the grant date.
• Following this transaction, Mr. Wheeler beneficially owns a total of 95,210 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to the Chief Financial Officer indicates continued alignment of management's interests with shareholder value and is a standard form of executive compensation.

Positives

• The grant of 60,000 restricted stock units to the Chief Financial Officer aligns management's long-term interests with those of shareholders.
• Increased beneficial ownership by a key executive demonstrates continued confidence in the company's future performance.

Future Outlook

The granted restricted stock units are scheduled to vest in three equal annual installments, with the first vesting occurring on the first anniversary of the grant date.

Industry Context

This transaction represents a standard form of equity compensation for executive officers in publicly traded companies, aiming to incentivize long-term performance and align executive interests with shareholder value.

Related Party Transactions

• Grant of 60,000 restricted stock units to Benjamin Richard Wheeler, the Chief Financial Officer, as part of the company's 2017 Employee, Director and Consultant Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of RSUs, but also increased alignment of executive incentives with long-term shareholder value.
• Employees: Reflects standard equity compensation practices within the company.

Next Steps

• RSUs will vest in three equal annual installments.
• First vesting installment occurs on the first anniversary of the grant date (August 16, 2026).

Key Dates

Keywords

Myriad Genetics, MYGN, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, CFO, Beneficial Ownership